Showing 1 - 7 results of 7 for search 'Brian H. Kushner', query time: 0.05s Refine Results
  1. 1
    Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

    Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival by Irene Y. Cheung, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung

    Published 2017-11-01
    Get full text
    Article
  2. 2
    Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine

    Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine by Irene Y. Cheung, Audrey Mauguen, Shakeel Modak, Ellen M. Basu, Yi Feng, Brian H. Kushner, Nai Kong Cheung

    Published 2024-05-01
    Get full text
    Article
  3. 3
    Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events

    Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Man... by Jaume Mora, Godfrey C. Chan, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornøe, Brian H. Kushner

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease

    Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease by Christina Fong, Brian H. Kushner, Angela Di Giannatale, Gunes Gundem, Shanita Li, Stephen S. Roberts, Ellen M. Basu, Anita Price, Nai-Kong V. Cheung, Shakeel Modak

    Published 2023-01-01
    Get full text
    Article
  5. 5
    The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

    The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial by Jaume Mora, Godfrey C. F. Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Jörg Faber, Arthur Wingerter, Melissa K. Bear, Alba Rubio-San-Simon, Blanca Martínez de Las Heras, Karen Tornøe, Maria Düring, Brian H. Kushner

    Published 2025-02-01
    Get full text
    Article
  6. 6
    Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

    Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study by Shakeel Modak, Jean-Benoit Le Luduec, Irene Y. Cheung, Debra A. Goldman, Irina Ostrovnaya, Ekaterina Doubrovina, Ellen Basu, Brian H. Kushner, Kim Kramer, Stephen S. Roberts, Richard J. O'Reilly, Nai-Kong V. Cheung, Katharine C. Hsu

    Published 2018-08-01
    Get full text
    Article
  7. 7
    Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

    Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies by Kim Kramer, Neeta Pandit-Taskar, Brian H. Kushner, Pat Zanzonico, John L. Humm, Ursula Tomlinson, Maria Donzelli, Suzanne L. Wolden, Sophia Haque, Ira Dunkel, Mark M. Souweidane, Jeffrey P. Greenfield, Satish Tickoo, Jason S. Lewis, Serge K. Lyashchenko, Jorge A. Carrasquillo, Bae Chu, Christopher Horan, Steven M. Larson, Nai-Kong V. Cheung, Shakeel Modak

    Published 2022-11-01
    Get full text
    Article

Search Tools: